Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Paul van Doesburg, CEO, Ipsen, Germany | The Monty
Ipsen - David Meek appointed as Chief Executive Officer of Ipsen http://www. ipsen.com/wp-content/uploads/2016/07/11-07-2016-PR-David-Meek-new-CEO-of- Ipsen.pdf | Facebook
Ipsen is officially recognized as a great place to work worldwide - Global
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen media library
Press releases
Press Releases - Ipsen UK
Combined Shareholders' Meeting of 27 May 2021
Pharma News and Updates | Ipsen, BioMarin, AbbVie, BMS, GSK, Novartis
Ipsen and Medetia join forces to accelerate early research in rare disease - Global
Press Releases - Ipsen UK
Press Releases - Ipsen UK
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
Press Releases / Melissa Peebles
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen CEO steers clear of gene therapy despite rare disease push
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
